A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer

Prior treatment

• Participants with Inflammatory breast cancer or leptomeningeal disease or brain metastases, with the exception of patients with definitively treated brain metastases that are clinically stable and asymptomatic for \>2 weeks and who are off or receiving low-dose corticosteroid treatment (\<=10 mg prednisone or equivalent) for at least 2 weeks prior to start of study treatment.
• Ongoing corticosteroid use \>10 mg/day (prednisone equivalent)
• Recent anticancer or investigational therapy within 14 days (28 days for fulvestrant)
• Major surgery within 28 days

Other illness

• Recent major bleeding or uncontrolled bleeding disorder
• Significant cardiovascular disease within 6 months or ongoing uncontrolled cardiac conditions
• Active or uncontrolled infection (controlled HIV or treated hepatitis C allowed)
• Uncontrolled renal, pancreatic, or liver disease (excluding stable conditions such as Gilbert's syndrome or liver metastases)
• Another malignancy requiring treatment within 2 years (except low-risk, curatively treated cancers)
• Any condition that may interfere with safety or study compliance

Other

• Untreated or unstable spinal cord compression
• Pregnancy or breastfeeding

• Female (assigned at birth), greater than or equal to (\>=) 18 years old, and able to provide informed consent
• Histologically confirmed metastatic or locally advanced breast cancer
• Postmenopausal status defined by surgical or natural menopause, or ovarian suppression with a GnRH agonist
• Prior therapy including
  • Must have received at least one endocrine therapy in the metastatic setting.
  • Must have received at least one cyclin-dependent kinase (CDK) 4/6i, either in the adjuvant and/or metastatic setting.
  • For Part 1 and Part 2 Cohorts 2A, 2B, 2C, and 2D: Participants may have received up to two prior distinct cytotoxic regimens (for example, taxanes, antibody-drug conjugates (ADCs), etc.) in the metastatic setting, unless discussed and approved by the medical monitor.
  • For Part 2 Cohort 2E: Participants must have received more than two prior distinct cytotoxic regimens (for example, taxanes, ADCs, etc.) in the metastatic setting.
• Radiologic disease progression on the most recent therapy
• Patients must have disease evaluable per response evaluation criteria in solid tumors (RECIST) v1.1
  • For Part 1 and Part 2B, 2C, and 2E: Participants may have either evaluable or measurable disease per RECIST v1.1.
  • For Part 2 Cohort 2A: Participants should have measurable soft tissue disease per RECIST v1.1.
  • For Part 2 Cohort 2D: Participants should have evaluable but not measurable disease.
• Willingness to provide baseline and on-treatment tumor biopsies, unless not feasible or medically appropriate
• For Part 1 and Part 2 (all cohorts):
  • Participants must have documented \>=10% ER staining and human epidermal growth factor receptor 2 (HER2) negative (per american society of clinical oncology \[ASCO\] college of american pathologists \[CAP\] guidelines) on the most recent tumor biopsy sample obtained.
  • For Part 2 Cohort 2B: Participants must have recent estrogen receptor 1 gene (ESR1) wild type from tumor or circulating tumor deoxy ribonucleic acid (ctDNA) testing performed after the most recent endocrine therapy prior to enrollment.
  • For Part 2 Cohort 2C: Participants must have ESR1 mutation detected from tumor or ctDNA testing performed prior to enrollment.
• Eastern cooperative oncology group (ECOG) performance status 0-1 and life expectancy of at least 3 months
• Adequate organ function Recovery from prior therapy-related toxicities to Grade \<=1 (except alopecia; neuropathy and endocrinopathies \<=Grade 2)
• Ability to swallow oral medication and comply with study procedures
• Stable dose (\>=30 days) of bisphosphonates or denosumab, if applicable